CRVO CERVOMED INC

CervoMed to Present at the Emerging Growth Conference

CervoMed to Present at the Emerging Growth Conference

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025.

Presentation Details

Format: Corporate Presentation

Date: Wednesday, October 22, 2025

Time: 11:25 – 11:55 AM ET

Webcast Link:

The webcast and replay of the presentation will be accessible in the Investor section of the CervoMed website .

About CervoMed

CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.

Investor Contact:

PJ Kelleher

LifeSci Advisors



617-430-7579



EN
20/10/2025

Underlying

CRVOCERVOMED INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERVOMED INC

 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Strengthens Board with Appointment of Life Sciences Business ...

CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced t...

8h / 38m 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Present at the Emerging Growth Conference

CervoMed to Present at the Emerging Growth Conference BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025. Presentation DetailsFormat: Corporate PresentationDate: Wednesday, October 22, 2025Time: 11:25 – 11:55 AM ETWebcast Link: The webcast and replay of the presenta...

October 20, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamap...

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer’s disease (AD) co-pathology Significant reduction in plasma levels of a well-established biomarker of neurodegeneration, plasma glial fibrillary acidic protein (GFAP), correlated to treatment response assessed by CDR-SB CervoMed antici...

October 8, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Busin...

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readiness BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnol...

October 7, 2025 1 EN
 PRESS RELEASE
Free
CRVO CERVOMED INC

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunitie...

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025. Panel DetailsTitle: “Small Firms Tackling Blockbuster Indications”Date: Thursday, Octobe...

October 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch